FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2241423248> ?p ?o ?g. }

• W2241423248 endingPage "348A" @default.
• W2241423248 startingPage "348A" @default.
• W2241423248 abstract "SESSION TITLE: Sepsis and Shock Posters SESSION TYPE: Original Investigation Poster PRESENTED ON: Wednesday, October 28, 2015 at 01:30 PM - 02:30 PM PURPOSE: Angiotensin II (ATII) is a naturally occurring hormone with important endocrine effects. It has recently been evaluated in a prospective randomized controlled trial for the treatment of high output shock. ATII has been administered to patients with a variety of medical conditions, and has only been shown to exacerbate one underlying disease, asthma. To date, however, there has been no effort to systematically review the side effects or adverse events associated with intravenous ATII. METHODS: We performed a comprehensive literature search of the administration of intravenous ATII to humans. Keywords included “intravenous administration, intravenous Injection, intravenous infusion, and angiotensin II.” We identified all studies which reported physiologic effects associated with the administration of ATII. Side effects were defined as physiological effects that were unintended or incongruous with the pressor effect of ATII. Adverse events were defined as deaths or serious morbidities that were attributable to ATII. RESULTS: 1193 studies were screened. 171 studies (3,291 participants) reported physiologic effects associated with ATII. The most commonly cited side effects included hyperaldosteronism and other disturbances of the renin-angiotensin-aldosterone (RAA) axis (40 studies), altered renal function (32 studies), other endocrine abnormalities (27 studies), and electrolyte disturbances (17 studies). Cardiac side effects were mentioned in 14 studies. The most serious side effect was bronchoconstriction or asthma, which was reported in 3 studies. Doses were reported most commonly in ng/kg/min with a range of 1 to 800 ng/kg/min (mean: 3.36 ± 6.62 ng/kg/min to 12.16 ± 16.84 ng/kg/min. No deaths or serious adverse events attributable to ATII were reported, though 23 patients in whom ATII was used to treat catecholamine-resistant septic shock died of their shock. Significant heterogeneity in study design prevented meta-analysis of results. CONCLUSIONS: The incidence of side effects associated with ATII is uncommon, and side effects are generally mild, with exacerbation of asthma being the most serious. The most commonly observed side effects were derangements with the RAA axis, kidney function and other endocrine abnormalities. CLINICAL IMPLICATIONS: Prospective, randomized controlled trials of the therapeutic use of ATII (at a dose range of 1ng/kg/min to 20ng/kg/min) as a pressor in catecholamine-resistant shock are ongoing. The analysis contained herein supports the idea that ATII may safely be studied in humans. DISCLOSURE: The following authors have nothing to disclose: Divya Chalikonda, Laurence Busse, David Yoo, Lakhmir Chawla Angiotensin II is being evaluated as a novel pressor agent for use in catecholamine resistant shock. This will be mentioned in my presentation adjunctively, though this is not the main point of my research." @default.
• W2241423248 created "2016-06-24" @default.
• W2241423248 creator A5009244008 @default.
• W2241423248 creator A5046633155 @default.
• W2241423248 creator A5062921449 @default.
• W2241423248 creator A5089235509 @default.
• W2241423248 date "2015-10-01" @default.
• W2241423248 modified "2023-09-30" @default.
• W2241423248 title "Side Effects and Adverse Events Associated With Intravenous Angiotensin II in Humans: A Systematic Review and Meta-analysis" @default.
• W2241423248 doi "https://doi.org/10.1378/chest.2268700" @default.
• W2241423248 hasPublicationYear "2015" @default.
• W2241423248 type Work @default.
• W2241423248 sameAs 2241423248 @default.
• W2241423248 citedByCount "0" @default.
• W2241423248 crossrefType "journal-article" @default.
• W2241423248 hasAuthorship W2241423248A5009244008 @default.
• W2241423248 hasAuthorship W2241423248A5046633155 @default.
• W2241423248 hasAuthorship W2241423248A5062921449 @default.
• W2241423248 hasAuthorship W2241423248A5089235509 @default.
• W2241423248 hasConcept C126322002 @default.
• W2241423248 hasConcept C197934379 @default.
• W2241423248 hasConcept C199360897 @default.
• W2241423248 hasConcept C2777628635 @default.
• W2241423248 hasConcept C2778384902 @default.
• W2241423248 hasConcept C2778525890 @default.
• W2241423248 hasConcept C2908929049 @default.
• W2241423248 hasConcept C3454156 @default.
• W2241423248 hasConcept C41008148 @default.
• W2241423248 hasConcept C46699223 @default.
• W2241423248 hasConcept C71315377 @default.
• W2241423248 hasConcept C71924100 @default.
• W2241423248 hasConcept C84393581 @default.
• W2241423248 hasConceptScore W2241423248C126322002 @default.
• W2241423248 hasConceptScore W2241423248C197934379 @default.
• W2241423248 hasConceptScore W2241423248C199360897 @default.
• W2241423248 hasConceptScore W2241423248C2777628635 @default.
• W2241423248 hasConceptScore W2241423248C2778384902 @default.
• W2241423248 hasConceptScore W2241423248C2778525890 @default.
• W2241423248 hasConceptScore W2241423248C2908929049 @default.
• W2241423248 hasConceptScore W2241423248C3454156 @default.
• W2241423248 hasConceptScore W2241423248C41008148 @default.
• W2241423248 hasConceptScore W2241423248C46699223 @default.
• W2241423248 hasConceptScore W2241423248C71315377 @default.
• W2241423248 hasConceptScore W2241423248C71924100 @default.
• W2241423248 hasConceptScore W2241423248C84393581 @default.
• W2241423248 hasIssue "4" @default.
• W2241423248 hasLocation W22414232481 @default.
• W2241423248 hasOpenAccess W2241423248 @default.
• W2241423248 hasPrimaryLocation W22414232481 @default.
• W2241423248 hasRelatedWork W1567525892 @default.
• W2241423248 hasRelatedWork W1966128948 @default.
• W2241423248 hasRelatedWork W1990045536 @default.
• W2241423248 hasRelatedWork W1992220075 @default.
• W2241423248 hasRelatedWork W2005733460 @default.
• W2241423248 hasRelatedWork W2024736606 @default.
• W2241423248 hasRelatedWork W2089758216 @default.
• W2241423248 hasRelatedWork W2116962665 @default.
• W2241423248 hasRelatedWork W2151139437 @default.
• W2241423248 hasRelatedWork W4282961419 @default.
• W2241423248 hasVolume "148" @default.
• W2241423248 isParatext "false" @default.
• W2241423248 isRetracted "false" @default.
• W2241423248 magId "2241423248" @default.
• W2241423248 workType "article" @default.